Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: Correlation with p53 functional status

International Journal of Cancer

Volumn 88, Issue 3, 2000, Pages 454-463

  Lee, Heuiran ^c   Kim, Jaesung ^a,b   Lee, Boyoung ^c   Chang, Jin Woo ^a,b   Ahn, Joongbae ^a,b   Park, Joon Oh ^a,b   Choi, Jene ^b   Yun, Chae Ok ^b   Kim, Byung Soo ^a,b   Kim, Joo Hang ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; E1A PROTEIN; E1B PROTEIN; GENE PRODUCT; ONCOLYTIC VIRUS; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; ESCHERICHIA COLI; GENE DELETION; GENE FUNCTION; GENE INDUCTION; GENE MUTATION; HEPATOMA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VIRUS ATTENUATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMAL; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; HUMAN; MALE; MICE; MICE, NUDE; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN P53; RECOMBINATION, GENETIC; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

EID: 0033809680     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T     Document Type: Article

References (45)

1. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
2. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
3. Molecular assessment of histopathological staging in squamous-cell carconoma of the head and neck
4. Abnormal structure and expression of p53 gene in human hepatocelluar carcinoma
5. Functional p53 protein in human papillomavirus-positive cancer cells
6. Implication of th ep53 tumorsuppressor gene in clinical oncology
7. Efficient generation of recombination adenovirus vectors by homologous recombination in Escherichia coli
8. E1A oncogene-induced cellular sensitization to immune mediated apoptosis is independent of p53 and resistant to blockade by E1B 19kDa protein
9. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
10. Trans E1 component requirments for maximal replication of E1-defective recombinant adenovims
11. P53 status does not determine out-come of E1B 55-kilodalton mutant adenovirus lytic infection
12. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
13. p53-Dependent cell death/apoptosis is required for a productive adenovirus infection
14. p53-Independent and -dependent requirements for E1B 55K in adenovirus type 5 replication
15. Clinical implications of the p53 tumor-suppressor gene
16. Targeting the replication of adenoviral gene therpy vectors to lung cancer cells: The importance of the adenoviral E1B-55kD gene
17. ONXY-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
18. Construction and propagation of human adenovirus vectors
19. Viral vector systems for gene therapy
20. ONYX-015: Clinical data are encouraging
21. Tumor-suppressor p53: Implications for tumor development and prognosis
22. p53 Mutation and MDM2 amplification in human soft tissue sarcomas
23. Role of cellular tumor necrosis factor receptor-associated factors in NF-kB activation and lymphocyte transformation by herpesvirus saimiri STP
24. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis
25. MDM2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations
26. Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway
27. Cancer gene therapy annual conference 1997: Trends and news
28. Molecular biology of cancer: Oncogenes
29. Gene therapy for cancer: What have we done and where are we going?
30. Replication of ONYX-015, a potential anticancer adeno-virus, is independent of p53 status in tumor cells
31. Basics of cancer gene therapy
32. The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53
33. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
34. Relief of p53-mediated transcriptional repression by the adenovirusE1B 19-kDa protein or the cellular Bcl-2 protein
35. Transcriptional and transforming activities of the adenovirus E1A proteins
36. The replicative capacities of large E1B-null group A and group C adenovirus are independent of host cell p53 status
37. Gene therapy-promises, problems and prospects
38. p53 Function and dysfunction
39. p53 Selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma
40. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
41. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
42. Advances in adenoviral vectors: From genetic engineering to their biology
43. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein